Southend residents face a stark disparity in access to a life-changing weight loss treatment, Mounjaro. While approximately 3.4 million people nationwide meet the eligibility criteria for this drug, the NHS plans to treat a mere 220,000 individuals over a three-year period. This disparity is further exacerbated by a financial incentive for GP surgeries: a £3,000 bonus for prescribing Mounjaro. However, the impact of this incentive is minimal, as a typical GP practice with 6,000 patients will have fewer than 20 individuals qualifying for the drug annually. The funding for the first year is expected to cover only a fraction of this number.
The situation in Southend is particularly dire, with the Liberal Democrats highlighting some of the most pronounced health divides in the country. A staggering 10.5-year gap in male life expectancy exists between the most and least affluent areas. Obesity, a key contributing factor to this divide, is a pressing issue for many residents. Unfortunately, the cost of Mounjaro, which can range from £160 to £310 per month, is a significant barrier for those who cannot afford private healthcare or prescriptions. This leaves many Southend residents feeling 'left behind' in the fight against obesity and its associated health consequences.
